CLINICAL_TRIALS
trial_result
· 2017-02-07
Clinical Trial Update: LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL) [Phase 1]
Summary
Phase 1 trial of LMP2a-specific cytotoxic T-lymphocytes for lymphoma has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Baylor College of Medicine | Conditions: Lymphoma | Phase 1 | Status: TERMINATED